Terms: = Skin cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Prognosis
18 results:
1. Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.
Zob DL; Augustin I; Caba L; Panzaru MC; Popa S; Popa AD; Florea L; Gorduza EV
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614156
[TBL] [Abstract] [Full Text] [Related]
2. Merkel cell polyomavirus-negative Merkel cell carcinoma is associated with JAK-STAT and MEK-ERK pathway activation.
Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Kohashi K; Kuwamoto S; Umekita Y; Oda Y
Cancer Sci; 2022 Jan; 113(1):251-260. PubMed ID: 34724284
[TBL] [Abstract] [Full Text] [Related]
3. Integrative pan-cancer analysis of mek1 aberrations and the potential clinical implications.
Zhou Z; Peng B; Li J; Gao K; Cai Y; Xu Z; Yan Y
Sci Rep; 2021 Sep; 11(1):18366. PubMed ID: 34526571
[TBL] [Abstract] [Full Text] [Related]
4. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
[TBL] [Abstract] [Full Text] [Related]
5. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
[TBL] [Abstract] [Full Text] [Related]
6. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
[TBL] [Abstract] [Full Text] [Related]
7. mek1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling.
Yang L; Ding JL
Front Immunol; 2019; 10():2020. PubMed ID: 31507609
[TBL] [Abstract] [Full Text] [Related]
8. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
[TBL] [Abstract] [Full Text] [Related]
9. Protein kinase C-α is upregulated by IMP1 in melanoma and is linked to poor survival.
Mahapatra L; Andruska N; Mao C; Gruber SB; Johnson TM; Fullen DR; Raskin L; Shapiro DJ
Melanoma Res; 2019 Oct; 29(5):539-543. PubMed ID: 30543563
[TBL] [Abstract] [Full Text] [Related]
10. MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma.
Fernandes JD; Hsieh R; de Freitas LA; Brandao MA; Lourenço SV; Sangueza M; Nico MM
Am J Dermatopathol; 2015 Dec; 37(12):892-7. PubMed ID: 26588333
[TBL] [Abstract] [Full Text] [Related]
11. Langerhans cell histiocytosis.
Grana N
Cancer Control; 2014 Oct; 21(4):328-34. PubMed ID: 25310214
[TBL] [Abstract] [Full Text] [Related]
12. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract] [Full Text] [Related]
13. The CDKN2A and MAP kinase pathways: molecular roads to primary oral mucosal melanoma.
Hsieh R; Nico MM; Coutinho-Camillo CM; Buim ME; Sangueza M; Lourenço SV
Am J Dermatopathol; 2013 Apr; 35(2):167-75. PubMed ID: 23000904
[TBL] [Abstract] [Full Text] [Related]
14. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
Patel SP; Kim KB
Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
[TBL] [Abstract] [Full Text] [Related]
15. mek1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract] [Full Text] [Related]
16. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
Board RE; Ellison G; Orr MC; Kemsley KR; McWalter G; Blockley LY; Dearden SP; Morris C; Ranson M; Cantarini MV; Dive C; Hughes A
Br J Cancer; 2009 Nov; 101(10):1724-30. PubMed ID: 19861964
[TBL] [Abstract] [Full Text] [Related]
17. SEREX identification of new tumor antigens linked to melanoma-associated retinopathy.
Hartmann TB; Bazhin AV; Schadendorf D; Eichmüller SB
Int J Cancer; 2005 Mar; 114(1):88-93. PubMed ID: 15523688
[TBL] [Abstract] [Full Text] [Related]
18. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells.
Aoudjit F; Guo W; Gagnon-Houde JV; Castaigne JG; Alcaide-Loridan C; Charron D; Al-Daccak R
Exp Cell Res; 2004 Sep; 299(1):79-90. PubMed ID: 15302575
[TBL] [Abstract] [Full Text] [Related]
